Abstract | PURPOSE: DESIGN: Systematic review and meta-analysis. METHODS: Following the PRISMA statement, PubMed, CINAHL, Cochrane and EMBASE were searched for eligible studies. FINDINGS: A total of 17 trials consisting of 1,052 patients were evaluated. Compared to placebo, there is low quality of evidence that nalbuphine was effective in reducing the incidence of pruritus in all patient population (RR, 0.66; 95% CI, 0.52 to 0.83; P = .0004) and obstetrics (RR, 0.81; 95% CI, 0.67 to 0.98; P = .03). We also found moderate quality of evidence that nalbuphine lowered pruritus in non-obstetrics, the number of rescue pruritus therapy and severity of pruritus episodes. However, nalbuphine did not cause sedation and affect pain scores. CONCLUSIONS:
|
Authors | Tito D Tubog, Jennifer L Harenberg, Kristina Buszta, Jennifer D Hestand |
Journal | Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses
(J Perianesth Nurs)
Vol. 34
Issue 3
Pg. 491-501.e8
(Jun 2019)
ISSN: 1532-8473 [Electronic] United States |
PMID | 30389225
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Copyright | Copyright © 2018 American Society of PeriAnesthesia Nurses. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Analgesics, Opioid
- Nalbuphine
|
Topics |
- Analgesics, Opioid
(administration & dosage, adverse effects)
- Female
- Humans
- Incidence
- Nalbuphine
(administration & dosage, adverse effects)
- Pain
(drug therapy)
- Pregnancy
- Pruritus
(chemically induced, epidemiology, prevention & control)
- Randomized Controlled Trials as Topic
|